One CRISPR treatment cut “bad” cholesterol in half for a full year — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cleveland Clinic researchers ran a first-in-human Phase 1 trial of CTX310 in 15 patients with lipid disorders that hadn't responded to medications, with doses ranging from 0.1 to 0.8 mg/kg delivered as a single infusion.
- Participants on the highest dose saw LDL cholesterol drop 52.5% and triglycerides fall 47.8% from baseline after 12 months, with no serious adverse events tied to the therapy across the full year of follow-up.
- Cleveland Clinic cardiologist Luke Laffin, the study's first author, called the durability of the lipid-lowering effect "impressive" and said the team will continue investigating CTX310 in more patients.
- CTX310 delivers CRISPR-Cas9 to the liver, where it switches off the ANGPTL3 gene that helps regulate fats circulating in the blood, lowering both LDL and triglycerides with a single edit.
- The findings were presented at the 2026 European Society of Cardiology annual meeting and published simultaneously in the New England Journal of Medicine.
- Researchers plan 15 more years of long-term safety monitoring per FDA guidance for gene-editing therapies, and the trial was funded by the therapy's developer, CRISPR Therapeutics AG of Zug, Switzerland.
Why it matters: For the small group of patients whose lipid disorders don't respond to standard drugs, a one-shot CRISPR infusion holding LDL down by 52.5% for a year is a real proof-of-concept — but with only 15 patients tested and 15 years of follow-up still required, CTX310 is years from routine clinical use and remains firmly experimental.
Ask SkimNews
